Search Result

Results for "

ROR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ROR (127) ADC Antibody (1) ADC Payload (1) Akt (3) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (13) Autophagy (2) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (1) Caspase (1) CD3 (1) CMV (1) Dihydroorotate Dehydrogenase (6) DNA/RNA Synthesis (1) Drug Isomer (1) Drug Metabolite (3) Drug-Linker Conjugates for ADC (2) Endogenous Metabolite (1) ERK (1) Fluorescent Dye (1) FXR (2) G protein-coupled Bile Acid Receptor 1 (3) GPR39 (1) GSK-3 (1) Histone Methyltransferase (1) Interleukin Related (5) Isotope-Labeled Compounds (3) JNK (1) LXR (4) Melatonin Receptor (1) Microtubule/Tubulin (1) mTOR (2) NF-κB (2) PARP (2) PD-1/PD-L1 (1) PI3K (1) PPAR (1) PROTACs (1) Reactive Oxygen Species (ROS) (3) Reference Standards (8) REV-ERB (2) SARS-CoV (2) Small Interfering RNA (siRNA) (6) STAT (1) Topoisomerase (1) Wnt (1)
By Research Areas:	Cancer (53) Cardiovascular Disease (3) Endocrinology (1) Infection (7) Inflammation/Immunology (89) Metabolic Disease (10) Neurological Disease (10)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (2) siRNAs (6)

144

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: ROR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10626

T0901317 Maximum Cited Publications 44 Publications Verification	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates FXR with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-14422

SR1078 10+ Cited Publications	ROR	Cancer
SR1078 is a selective agonist of retinoic acid receptor-related orphan receptor α/γ (*RORα/RORγ). SR1078 directly binds to the ligand binding domain of RORα and RORγ and increases the transcriptional activity of these receptors, leading to stimulation of ROR*α/γ target gene transcription .

HY-12776

GSK805 5 Publications Verification	ROR	Inflammation/Immunology
GSK805 is an orally active and CNS penetrant RORγt inhibitor. GSK805 inhibits RORγ and Th17 cells differentiation with pIC₅₀ values of 8.4 and >8.2. GSK805 inhibits the function of Th17 cells. GSK805 can be used for the research of immunity .

HY-13421

SR1001 5+ Cited Publications	REV-ERB ROR	Inflammation/Immunology
SR1001 is a selective RORα and RORγt inverse agonist with K_is 172 and 111 nM, respectively.

HY-14413

SR3335 10+ Cited Publications ML 176	ROR	Metabolic Disease
SR3335 (ML 176) is a selective RORα inverse agonist that directly binds to RORα with a K_i of 220 nM .

HY-P99201

Zilovertamab 2 Publications Verification UC-961; Cirmtuzumab	ROR Wnt	Cancer
Zilovertamab (UC-961) is a humanised monoclonal antibody against *ROR1* that blocks Wnt5a-induced ROR1 signalling .

HY-104037

Cintirorgon 5+ Cited Publications LYC-55716	ROR	Cancer
Cintirorgon (LYC-55716) is a first-in-class, selective and orally bioavailable RORγ agonist. Cintirorgon (LYC-55716) modulates gene expression of RORγ expressing T lymphocyte immune cells, resulting in enhanced effector function, as well as decreased immunosuppression, resulting in decreased tumor growth, and improved survival .

HY-16998

SR2211 1 Publications Verification	ROR	Inflammation/Immunology
SR2211 is a potent, selective synthetic RORγ modulator and functions as an inverse agonist, with a K_i of 105 nM and an IC₅₀ of ~320 nM.

HY-152851

Izumerogant IMU-935	ROR Dihydroorotate Dehydrogenase SARS-CoV CMV	Infection
Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC₅₀s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC₅₀ values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties .

HY-19770

GSK2981278 4 Publications Verification	ROR	Inflammation/Immunology
GSK2981278 is a potent and selective RORγ inverse agonist. GSK2981278 inhibits activation of the il17 promoter and interferes RORγ-DNA binding .

HY-126037

(±)-ML 209 1 Publications Verification	ROR	Inflammation/Immunology
(±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC₅₀ of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC₅₀ of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4 ⁺ T cells into other lineages, including Th1 and regulatory T cells .

HY-139534

ARI-1 1 Publications Verification	ROR Apoptosis Akt mTOR PARP	Cancer
ARI-1 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor. ARI-1 blocks the PI3K/AKT/mTOR signaling pathway in a ROR1-dependent manner. ARI-1 upregulates cleaved-PARP and p-P38. ARI-1 induces Apoptosis. ARI-1 has anticancer activity against non-small cell lung cancer .

HY-137434

Cedirogant ABBV-157	ROR	Inflammation/Immunology
Cedirogant (ABBV-157) is an orally active RORγt inverse agonist. Cedirogant can be used for psoriasis research .

HY-145627

Ozuriftamab vedotin BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .

HY-120210

XY018	ROR	Inflammation/Immunology Cancer
XY018 is a potent *ROR-γ*-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC₅₀, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD) .

HY-155487

JTE-151	ROR	Neurological Disease Inflammation/Immunology
JTE-151 is a RORγ inhibitor, which can suppress overactive immune response through inhibition of RORγ related to the activation of Th17 cells, making JTE-151 possible to be used in autoimmune disease research .

HY-102075A

TMP778	ROR	Inflammation/Immunology
TMP778 is a potent and selevtive RORγt inverse agonist, with an IC₅₀ of 7 nM in FRET assay.

HY-19774

GNE-0946	ROR	Inflammation/Immunology
GNE-0946 is a potent and selective RORγ( RORc) agonist with an EC₅₀ value of 4 nM for HEK-293 cell.

HY-W150866

Hexyl 4-hydroxybenzoate Hexylparaben	ROR	Inflammation/Immunology
Hexyl 4-hydroxybenzoate (Hexylparaben) is a retinoic acid-related orphan receptor RORγ(t) agonist with an EC₅₀ of 144 nM. Hexyl 4-hydroxybenzoate is used in the study of autoimmune diseases .

HY-160806

(5-Cl)-Exatecan	ADC Payload Topoisomerase	Cancer
(5-Cl)-Exatecan is a derivative of Exatecan (HY-13631) and a DNA topoisomerase inhibitor. (5-Cl)-Exatecan serves as the cytotoxic payload component in antibody-drug conjugates (ADC) targeting *ROR1*-positive cancers. (5-Cl)-Exatecan is applicable for the research of *ROR1*-positive cancers .

HY-111509

TAK-828F	ROR	Inflammation/Immunology
TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC₅₀=1.9 nM, reporter gene IC₅₀=6.1 nM). TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ) .

HY-119366

S18-000003	ROR	Inflammation/Immunology
S18-000003 is a potent, selective and orally active inhibitor of *retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC₅₀* of <30 nM towards human RORγt in competitive binding assays. S18-000003 shows selectivity for RORγt over other ROR family members (IC₅₀>10 μM). S18-000003 can be used for the research of psoriasis with low risk of thymic aberrations .

HY-117819

TMP920	ROR	Inflammation/Immunology
TMP920 is a highly potent and selective RORγt antagonist. TMP920 inhibits RORγt binding to the SRC1 peptide with an IC₅₀ of 0.03 μM .

HY-142834

RORγt/DHODH-IN-2	ROR Dihydroorotate Dehydrogenase	Inflammation/Immunology
RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research .

HY-131338

RORγt inverse agonist 13 1 Publications Verification	ROR	Inflammation/Immunology
RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved agent-like properties, with an IC₅₀ of 63.8 nM .

HY-103637

Vimirogant VTP-43742	ROR	Inflammation/Immunology
Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant has the potential for autoimmune disorders research .

HY-142934

RORγt inhibitor 2	ROR	Inflammation/Immunology Cancer
RORγt inhibitor 2 (Compound 119) is a potent RORγt inhibitor with an IC₅₀ of 9.2 nM. RORγt inhibitor 2 can be used for the research of cancer, inflammation or autoimmune diseases mediated by RORγt .

HY-138007

SR-1903	ROR PPAR LXR	Metabolic Disease Inflammation/Immunology
SR-1903 is an inverse agonist of RORγ and PPARγ (IC₅₀ of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .

HY-103637A

Vimirogant hydrochloride 1 Publications Verification VTP-43742 hydrochloride	ROR	Inflammation/Immunology
Vimirogant (VTP-43742) hydrochloride is a potent, selective, and orally active RORγt inhibitor (K_i=3.5 nM; IC₅₀=17 nM). Vimirogant hydrochloride exhibits >1000-fold selectivity versus the RORα and RORβ isotypes. Vimirogant hydrochloride inhibits Th17 differentiation and IL-17A secretion from mouse splenocytes (IC₅₀=57 nM) without affecting Th1, Th2, or Treg cell differentiation. Vimirogant hydrochloride has the potential for autoimmune disorders research .

HY-128604

XY101	ROR	Cancer
XY101 is a potent, selective, metabolically stable and orally available RORγ inverse agonist with an IC₅₀ of 30 nM and a K_d of 380 nM .

HY-136527

BMS-986251	ROR Interleukin Related	Inflammation/Immunology
BMS-986251 is an orally active and selective RORγt inverse agonist with an EC₅₀ of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC₅₀ of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis) .

HY-174382

ROR1-IN-3	Akt mTOR NF-κB ROR Apoptosis	Cancer
ROR1-IN-3 (Compound 24d) is a potent and highly selective *ROR1* kinase inhibitor (IC₅₀ = 17.6 nM). ROR1-IN-3 demonstrates robust antitumor activity and inhibitory effect against ROR1 both in vitro and in vivo. ROR1-IN-3 has robust antiproliferative efficacy in vitro and in vivo. ROR1-IN-3 induces apoptosis in cancer cell lines. ROR1-IN-3 inhibits ROR1 downstream AKT/mTOR and NF-κB signaling pathway. ROR1-IN-3 can be studied in antitumor research .

HY-175497

ROR1-IN-4	ROR Apoptosis Bcl-2 Family PARP	Cancer
ROR1-IN-4 is a selective *ROR1* inhibitor with a K_d of 52 nM. ROR1-IN-4 shows potent anti-proliferative activity against TNBC cell line MDA-MB-231 (IC₅₀ = 75 nM). ROR1-IN-4 reduces colony formation, induces apoptosis and inhibits the phosphorylation of *ROR1* (Tyr786) in MDA-MB-231 cells. ROR1-IN-4 demonstrates superior anti-tumor efficacy in nude mice bearing MDA-MB-231 subcutaneous xenografts. ROR1-IN-4 can be used for the study of triple-negative breast cancer (TNBC) .

HY-170995

*PROTAC ROR1 degrader-1*	PROTACs ROR Apoptosis	Cancer
PROTAC ROR1 degrader-1 (Compound 11d) is a PROTAC degrader for pseudokinase *ROR1* that degrades *ROR1* in NSCLC cells with a DC₅₀s of 40-80 nM. PROTAC ROR1 degrader-1 causes the cleavage of PARP and induces apoptosis in NCI-H23 . (Pink: ligand for target protein ROR1 ligand-1 (HY-170996); Black: linker (HY-W014787); Blue: ligand for VHL E3 ligase (S,R,S)-AHPC (HY-125845))

HY-175490

RORγ inverse agonist 2	ROR	Inflammation/Immunology
RORγ inverse agonist 2 (Compound 15) is a potent inverse agonist of the *retinoic acid receptor-related orphan receptor RORγ, with IC₅₀* values of 0.4 and 0.9 μM for Gal4-RORγ and full-length RORγ, respectively. RORγ inverse agonist 2 is useful in the study of autoimmune diseases .

HY-177712

RORγt inverse agonist 36	ROR	Inflammation/Immunology
RORγt inverse agonist 36 (S configuration of Compound 16) is a RORγt inverse agonist. RORγt inverse agonist 36 can be used for the research of inflammation and immunology .

HY-128573

RORγt Inverse agonist 3	ROR	Neurological Disease
RORγt Inverse agonist 3 is a potent, selective and orally active RORγ inverse agonist, with EC₅₀s of 0.22 μM and 0.15 μM for hRORγ and RORγt (human IL-17 cells), respectively .

HY-155542

RORγ antagonist 1	ROR	Cancer
RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of RORγ (K_D=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and AKT/mTORC1 pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells .

HY-176190

ROR1-IN-2	ROR	Cancer
ROR1-IN-2 (compound 9I) is a potent and selective *ROR1* inhibitor. ROR1-IN-2 exhibits antiproliferative activity in multiple cancer cells. ROR1-IN-2 significantly suppresses tumor growth in vivo .

HY-162490

TF-S14	ROR	Inflammation/Immunology
TF-S14 is a reverse agonist of RORγt. TF-S14 reduces Th17 cell-associated cytokine production, including IL-17A, IL-21, and IL-22 by binding to and inhibiting RORγt activity. TF-S14 can be used in the study of autoimmune diseases and rejection in allotransplantation .

HY-170996

ROR1 ligand-1	ROR	Cancer
ROR1 ligand-1 (9-1) is a ligand for PROTACT *ROR1* degrader-1 (HY-170995). ROR1 ligand-1 connects with VHL-type or CRBN ligand to design and synthesize the first selective and potent of *ROR1* PROTACs .

HY-RS12125

ROR2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ROR2 Human Pre-designed siRNA Set A contains three designed siRNAs for ROR2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROR2 Human Pre-designed siRNA Set A ROR2 Human Pre-designed siRNA Set A

HY-RS16801

Ror1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ror1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ror1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ror1 Mouse Pre-designed siRNA Set A Ror1 Mouse Pre-designed siRNA Set A

HY-RS12124

ROR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ROR1 Human Pre-designed siRNA Set A contains three designed siRNAs for ROR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROR1 Human Pre-designed siRNA Set A ROR1 Human Pre-designed siRNA Set A

HY-128353

ROR agonist-1	ROR	Inflammation/Immunology
ROR agonist-1 is a potent and orally bioavailable inverse agonist of the retinoic acid receptor-related orphan receptor C2 (RORC2), inhibition of IL-17A production from human primary T_H 17 cells with a pIC₅₀ of 7.5 .

HY-170370

RORγt inverse agonist 34	ROR	Inflammation/Immunology
RORγt inverse agonist 34 (compound 5a) is a RORγt inverse agonist with an IC₅₀ of 0.094 μM for RORγt-LBD. RORγt inverse agonist 34 is used for psoriasis research .

HY-126321

RORγt agonist 1	ROR	Cancer
RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC₅₀ of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy .

HY-122737

RORγt Inverse agonist 8	ROR	Inflammation/Immunology
RORγt Inverse agonist 8 is a potent, selective, orally bioavailable RORγt inverse agonist, with an IC₅₀ of 19 nM for human RORγt-LBD .

HY-19510

RORγt inhibitor 4	ROR	Neurological Disease Inflammation/Immunology
RORγt inhibitor 4 (Compound 9a) is an orally active and a CNS-penetrating RORγt inhibitor. RORγt inhibitor 4 improves experimental autoimmune encephalomyelitis .

HY-49076

RORγ inverse agonist 1	ROR	Cancer
RORγ inverse agonist 1 is the inverse agonist of RORγ .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0155

Nobiletin Maximum Cited Publications 27 Publications Verification	Flavonoids Neurological Disease Classification of Application Fields Flavones Rutaceae Plants Inflammation/Immunology Disease Research Fields Citrus reticulata Blanco Source Classification	ROR Reactive Oxygen Species (ROS) Apoptosis Autophagy
Nobiletin is a poly-methoxylated flavone from the citrus peel that improves memory loss. Nobiletin is a retinoid acid receptor-related orphan receptors (RORs) agonist. Nobiletin can reduce reactive oxygen species (ROS) levels in differentiated C2C12 myotubes and has anti-inflammation and anti-cancer properties, including anti-angiogenesis, anti-proliferation, anti-metastasis and induced apoptosis .

HY-143712

Allolithocholic acid 1 Publications Verification	Structural Classification Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	Drug Metabolite G protein-coupled Bile Acid Receptor 1 ROR
Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC₅₀ = 2.7 μM) and RORγt inverse agonist (IC₅₀ = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .

HY-N2253

Neoruscogenin 1 Publications Verification	Liliaceae Plants Ruscus aculeata Linn. Steroids Source Classification	ROR
Neoruscogenin, a member of the steroidal sapogenin family, is a high-affinity agonist of the nuclear receptor RORα (NR1F1) (EC₅₀ = 0.11 µM) .

HY-135319

Strictinin	Structural Classification Phenols Polyphenols Camellia sinensis (L.) O. Ktze. Plants Source Classification Theaceae	Bacterial Antibiotic ERK JNK NF-κB ROR Apoptosis Caspase GSK-3 Akt PI3K
Strictinin is an orally active phenolic compound. Strictinin reduces xanthine oxidase activity, uric acid production, and the activation of ERK1/2, JNK, NF-κB, and NLRP3 inflammasome components in hepatocytes treated with Xanthine (HY-W017389). Strictinin decreases elevated serum uric acid levels and enhanced xanthine oxidase activity in mice treated with potassium oxonate. Strictinin acts as a *ROR1* inhibitor and exhibits anticancer activity against highly aggressive non-androgen-dependent prostate cancer. Strictinin induces cancer cell apoptosis (apoptosis), arrests cell cycle, and inhibits cancer cell migration, invasion, and epithelial-mesenchymal transition. Strictinin modulates gut microbiota, inhibits bacterial growth and biofilm formation, accelerates small intestinal transit, and blocks viral entry and replication. Strictinin can be used in research related to hyperuricemia, androgen receptor-negative non-androgen-dependent prostate cancer, triple-negative breast cancer, bacterial infections, constipation, coronavirus infections, dental caries, and infections caused by influenza A, influenza B, and human parainfluenza virus type 1 .

HY-N0155R

Nobiletin (Standard)	Structural Classification Flavonoids Flavones Rutaceae Plants Citrus reticulata Blanco Source Classification	Reference Standards ROR Reactive Oxygen Species (ROS) Apoptosis Autophagy
Nobiletin (Standard) is the analytical standard of Nobiletin. This product is intended for research and analytical applications. Nobiletin is a poly-methoxylated flavone from the citrus peel that improves memory loss. Nobiletin is a retinoid acid receptor-related orphan receptors (RORs) agonist. Nobiletin can reduce reactive oxygen species (ROS) levels in differentiated C2C12 myotubes and has anti-inflammation and anti-cancer properties, including anti-angiogenesis, anti-proliferation, anti-metastasis and induced apoptosis .

HY-N2253R

Neoruscogenin (Standard)	Structural Classification Liliaceae Plants Ruscus aculeata Linn. Steroids Source Classification	Reference Standards ROR
Neoruscogenin (Standard) is the analytical standard of Neoruscogenin. This product is intended for research and analytical applications. Neoruscogenin, a member of the steroidal sapogenin family, is a high-affinity agonist of the nuclear receptor RORα (NR1F1) (EC₅₀ = 0.11 μM) .

HY-N16465

Cinnamtannin D1	Phenols Polyphenols Plants Lauraceae Lindera glauca (Siebold & Zucc.) Blume Source Classification	Apoptosis Reactive Oxygen Species (ROS) STAT
Cinnamtannin D1 is an orally active polyphenolic compound with immunosuppressive activity. Cinnamtannin D1 regulates the balance of Th17/Treg cells by inhibiting AHR expression. Cinnamtannin D1 reduces apoptosis and ROS in INS-1 cells and primary cultured murine islets induced by Palmitic acid (PA) (HY-N0830). Cinnamtannin D1 reduces Th17 cell differentiation via downregulating *p-STAT3*/RORγt and promotes Treg cell differentiation via upregulating p-STAT5/Foxp3. Cinnamtannin D1 exerts excellent anti-arthritic efficacy in collagen-induced arthritis (CIA) model of mice. Cinnamtannin D1 can be used for the study of rheumatoid arthritis (RA) .

HY-143712R

Allolithocholic acid (Standard)	Structural Classification Endogenous metabolite Steroids Source Classification	Reference Standards Drug Metabolite G protein-coupled Bile Acid Receptor 1 ROR
Allolithocholic acid (Standard) is the analytical standard of Allolithocholic acid (HY-143712). This product is intended for research and analytical applications. Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC₅₀ = 2.7 μM) and RORγt inverse agonist (IC₅₀ = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .

Cat. No.	Product Name	Chemical Structure

HY-143712S1

Allolithocholic Acid-d4

Allolithocholic Acid-d₄ (3α-hydoxy-5α-Cholaoic Acid-d₄, allo-LCA-d₄) is deuterium labeled Allolithocholic acid (HY-143712). Allolithocholic acid is an orally active metabolite of Lithocholic acid (HY-B0172). Allolithocholic acid is a dual GPBAR1 agonist (EC₅₀ = 2.7 μM) and RORγt inverse agonist (IC₅₀ = 3.4 μM). Allolithocholic acid modulates immune and metabolic pathways, regulates immune cell polarization, prevents M1 macrophage and Th17 CD4 cell polarization. Allolithocholic acid improves insulin sensitivity, reduces liver lipid accumulation, reverses liver immunological, inflammatory and metabolic signaling dysregulation, restores bile acid homeostasis, adipose tissue histopathology/function, and intestinal microbiota composition, modulates intestinal immunity. Allolithocholic acid can be used for the researches of cancer, inflammayion, immunology and metabolic disease .

HY-169220S

RORγ/DHODH-IN-1
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC₅₀ values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5) .

HY-169222S

RORγ/DHODH-IN-2
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC₅₀ values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC₅₀ values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .

HY-125801S

3-Oxo-5β-cholanoic acid-d4
3-Oxo-5β-cholanoic acid-d₄ (Dehydrolithocholic acid-d₄) is the deuterium labeled 3-Oxo-5β-cholanoic acid (HY-125801). 3-Oxo-5β-cholanoic acid (Dehydrolithocholic acid), a bile acid metabolite, inhibits the diferentiation of TH17 cells by directly binding to the key transcription factor RORγt (K_d=1.13 μM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks